Pharmaceutical Working Group Position Paper 2017/2018 - 制药工作组建议书2017/2018 Go back »

  • Published on:
  • Category:
    Position Paper
  • by:
    Pharmaceutical Working Group / Forum
  • Keywords:


The Pharmaceutical Working Group represents about 40 international pharmaceutical manufacturing companies operating in China. The working group encourages government policies that support the creation of a sustainable ecosystem that fosters innovation and healthy growth of the pharmaceutical industry as a whole, while improving patient access to innovative, high quality medicines, in line with China's declared strategic objectives for the healthcare sector. Policies related to Intellectual Property (IP), pricing and reimbursement are potentially the most useful tools for rewarding quality and safety while creating incentives for domestic and multinational companies alike to bring innovative medicines to the Chinese market. The working group supports the establishment of a transparent regulatory environment whereby the solicitation of comments and participation from the pharmaceutical industry (both local and foreign) form an integral part of policy setting, particularly on issues such as pricing, reimbursement and intellectual property rights (IPR) .

Related documents

Annual Working Group Report 2017 - Pharmaceutical

Pharmaceutical Working Group Position Paper 2018/2019 - 制药工作组建议书2018/2019

Annual Working Group Report 2016 Pharmaceutical

Related EURObiz articles